GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs... Show more
GMR Solutions Inc., operating through its Global Medical Response business, is the largest provider of emergency medical services in the United States. The company supports roughly 5.5 million patient encounters annually, employs about 34,000 team members, and operates across approximately 1,400 counties covering around 60% of the U.S. population. Its portfolio spans ground ambulance operations under American Medical Response as well as multiple air medical brands, including Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.
This national, fully integrated air-and-ground footprint is a meaningful competitive moat in an otherwise fragmented industry. Management has described a "land and expand" strategy in which a strong ground presence in a community creates a path to win adjacent air business, local EMS contracts, and smaller tuck-in acquisitions. The structural case rests on several durable tailwinds: an aging population, rising patient encounter volumes, and continued rural hospital closures that increasingly route patients to 911 and EMS providers as their first point of care. Because most contracts include inflation-linked (CPI-plus) rate escalation, the company also has a built-in mechanism to partially offset cost inflation.
The principal structural risk is reimbursement pressure. With commercial insurance and managed care representing more than half of net transport revenue, and government payors comprising a substantial additional share, shifts in payor mix, rate changes, or collectability could compress margins even as volume grows.
Several forward-looking events are likely to influence investor sentiment. First, quarterly earnings updates will be scrutinized for progress against full-year 2026 guidance, particularly the gap between revenue growth and Adjusted EBITDA growth. Management has pointed to innovation-driven efficiency and cross-selling as key drivers of that margin expansion.
Second, the evolution of the company's capital allocation plan is a focal point. Management has signaled an intent to prioritize de-leveraging, including a term-loan repricing and a commitment to use approximately $200 million to reduce debt. At the same time, executives have indicated an active but selective M&A pipeline focused on adjacent markets, suggesting that any announced transaction could act as a sentiment catalyst in either direction.
Third, regulatory and legislative developments around reimbursement remain a watch item. Federal and state "surprise medical billing" rules and scrutiny of private-equity involvement in healthcare could affect pricing power and acquisition flexibility. Finally, as a relatively recent public listing, the company's analyst coverage is still maturing. Any initial ratings, price targets, or consensus recommendation shifts could meaningfully influence how the stock is valued relative to healthcare-services peers.
The company's trajectory is closely tied to healthcare policy and demographic trends rather than traditional consumer discretionary cycles. An aging U.S. population and the continued closure of rural hospitals are secular drivers that tend to increase demand for EMS and out-of-hospital care independent of short-term economic swings.
On the macro side, inflation and labor costs are direct margin inputs. Fuel prices affect air ambulance operations, while wage pressure in a competitive clinical labor market can raise operating costs. The CPI-linked escalation built into many contracts provides some offset, but it also means the company's realized revenue growth is partly a function of the broader inflation environment. Interest rates matter as well: a higher cost of capital can slow M&A activity and raise financing costs, while the company's stated de-leveraging strategy could improve its financial flexibility as rates normalize. Weather patterns also introduce operational volatility for air transport, which is exposed to cancellation rates during adverse conditions.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The engine is built to assist users in identifying developing trends, evaluating potential breakouts or reversals, and exploring predictions across a broad universe of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support more informed decision-making. For investors tracking GMRS, the Trend Prediction Engine can be a useful complement to fundamental research by offering a data-driven view of short-term directional signals.
Heading into 2026, the most important themes are execution against guidance, margin durability, and balance-sheet transformation. If the company can sustain same-market revenue growth while converting innovation and cross-selling into higher EBITDA margins, it would reinforce the thesis that scale and integration translate into operating leverage.
Longer term, market expansion remains a key driver. The "land and expand" model and tuck-in acquisitions offer a path to densify the company's network and strengthen negotiating positions with payors. Cost structure evolution will hinge on clinical labor efficiency, fuel and maintenance discipline, and the adoption of technology such as Nurse Navigation that can shift demand toward lower-cost care pathways.
Competitive threats include regional ground and air ambulance providers, hospital-owned transport operations, and potential new entrants in mobile integrated healthcare. Regulatory developments—particularly around surprise billing, government reimbursement rates, and private-equity oversight—represent the most significant exogenous risks. Capital allocation priorities, balancing debt reduction against selective M&A, will be closely watched as a signal of management's confidence and discipline. As analyst coverage matures, consensus expectations around these themes will likely become a more important driver of the stock's valuation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry HospitalNursingManagement
The 10-day RSI Indicator for GMRS moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 1 instances where the indicator moved out of the overbought zone. In 1 of the 1 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMRS as a result. In 4 of 6 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for GMRS turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 4 similar instances when the indicator turned negative. In 4 of the 4 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GMRS moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for GMRS crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRS advanced for three days, in 14 of 20 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
GMRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 9 of 14 cases where GMRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.851) is normal, around the industry mean (204.532). P/E Ratio (-6.129) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.502) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. GMRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.